NEW YORK (GenomeWeb) – Admera Health today announced it has completed a Series A financing round.

The New Jersey-based molecular diagnostics firm did not disclose the sum raised in the funding round, but said it is planning to use the capital to "expand operations aggressively" and accelerate product development efforts.

The financing round was led by investment firm Prime Value Capital Management (PVCM) and was joined by Sungent Bioventure, a venture capital firm based in Suzhou, China. PVCM's founding partner Chenhui Wen will join Admera's board of directors, Admera said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.